Talquetamab
- Generic Name
- Talquetamab
- Brand Names
- Talvey
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2226212-40-2
- Unique Ingredient Identifier
- 4W3KFI3TN3
- Background
Talquetamab is a IgG4-PAA bispecific G protein-coupled receptor class C group 5 member D (GPRC5D)-directed CD3 T-cell engager. It consists of two arms - anti-GPRC5D and anti-CD3 arms - linked by two interchain disulfide bonds, each arm comprising a heavy and light chain. Talquetamab binds to GPRC5D, a cell surface receptor expressed predominantly on multiple...
- Indication
In the US, talquetamab is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. In Europe, talquetamab is indicated in patients who received at least three prior therap...
- Associated Conditions
- Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 480
- Registration Number
- NCT04634552
- Locations
- 🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸City of Hope, Duarte, California, United States
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 228
- Registration Number
- NCT04586426
- Locations
- 🇨🇦
Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
🇺🇸University of Alabama at Birmingham, Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 290
- Registration Number
- NCT04108195
- Locations
- 🇨🇦
Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California, United States
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Celgene
- Target Recruit Count
- 264
- Registration Number
- NCT03601078
- Locations
- 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 320
- Registration Number
- NCT03399799
- Locations
- 🇪🇸
Hosp. Univ. Germans Trias I Pujol, Badalona, Spain
🇪🇸Hosp Univ Fund Jimenez Diaz, Madrid, Spain
🇪🇸Clinica Univ. de Navarra, Pamplona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.